🔗 Share this article

While the United States undertakes historic changes to its immunization recommendations, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by questioning COVID-19 vaccinations in the pandemic and has concentrated on potential deaths following COVID-19 immunization in her recent time at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Schedule

Health officials were set to reveal sweeping changes to the childhood vaccine schedule recently, aligning the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US out of step with much of the international standard with no evidence for improved outcomes. This reveal has been delayed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this year.

Consolidating Power at the Regulatory Body

This interim role may indicate a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting certain childhood immunization guidelines in the US in order to be more like the Danish model, a society with nationalized medicine and a population roughly the size of Wisconsin’s.

In her initial comments, she has continued to focus on vaccination policy – usually the domain of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Background

Høeg has no obvious track record in medication creation, oversight or administrative roles, which has been customary for former directors of the CBER. She has served at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for leading the CDER, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a major agency. She has no expertise in industry regulation.”

Former heads of the center would “be deeply familiar with legal statutes and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Frankly, she lacks the type of experience that former directors who led CBER have had.”

This division has an enormous portfolio at the agency, the former commissioner emphasized.

“The public just zeroes in on the innovative therapies, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and all of those must be supervised,” Woodcock noted. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant management element to the role, which manages over 5,000 employees. “It is a massive leadership role, if you execute it properly,” Woodcock said.

Official Statement and Contentious Initiatives

In response to questions about Dr. Høeg's qualifications and whether this appointment indicates greater collaboration among regulatory chiefs on vaccines, a representative stated that the “inquiries are based on flawed presumptions”.

“Her experience is consistent with the responsibilities of her position,” the representative stated, noting the time Høeg spent counseling the agency head on “medication safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg takes over the agency head's new priority voucher program, a disputed rapid drug-approval program that apparently concerned her predecessors. “How are these therapies being picked for this fast-track system? Who takes the decisions?” Howard asked. “There is a lot of lack of transparency occurring at the regulatory body right now.”

In general, he said, “the agency appears to be shifting towards laxer rules of all drugs, except for vaccines.”

Established Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if concerning, past, critics have noted. She authored a research paper using unverified crowd-sourced reports to determine the incidence of myocarditis following COVID-19 vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the new federal leadership encompassed altering rules for novel immunizations and halting “optional” vaccines, she stated after the election on a audio program. At the agency, Høeg has allegedly proposed barring teenage boys from getting COVID-19 vaccines.

“She is an all-around dogmatist who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a highly disingenuous, fraudulent way,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow contrarians, {like|